Am J Ind Med
- CAREY RN, Reid A, de Klerk N, Cinquini P, et al
Mortality and Cancer Incidence After Exposure to Blue Asbestos in Childhood: A
Further 10 Years of Follow-Up.
Am J Ind Med. 2025;68:772-783.
Ann Surg Oncol
- XING Y, Zhou J, Yang Z, Dai Z, et al
Visible Pleural Retraction is a Prognostic Marker in Early-Stage Non-Small Cell
Lung Cancer: A Retrospective Cohort Study.
Ann Surg Oncol. 2025 Aug 9. doi: 10.1245/s10434-025-17946.
- UEDA D, Mimae T, Okada M
Reply to: "Should Muscle Mass be Incorporated into Surgical Decision Making for
Early-Stage Lung Cancer?", by Yan et al.
Ann Surg Oncol. 2025 Aug 9. doi: 10.1245/s10434-025-18049.
- HUANG K, Li P, Wu Q, Tang X, et al
Sleeve Lobectomy, Pulmonary Artery Plasty, and Superior Vena Cava Reconstruction
for Locally Advanced Non-small Cell Lung Cancer: A Single-Center Retrospective
Study.
Ann Surg Oncol. 2025 Aug 8. doi: 10.1245/s10434-025-17652.
Ann Thorac Surg
- GRIFFITH A, Pratt CG, Whitrock JN, Moore AN, et al
Achieving Equitable Care for Racial Minority Patients with a Lung Cancer
Screening Program.
Ann Thorac Surg. 2025 Aug 12:S0003-4975(25)00749.
- EZENWANKWO E
Securing CT Lung Cancer Screening Access: Implications of the Supreme Court's
Ruling in Kennedy v. Braidwood.
Ann Thorac Surg. 2025 Aug 12:S0003-4975(25)00755.
- ABDALLAT M, Leo RT, Sugarbaker EA, McAllister M, et al
Segmentectomy vs Lobectomy for Occult N1 in Non-Small Cell Lung Cancer: Is Less
Still More?
Ann Thorac Surg. 2025 Aug 8:S0003-4975(25)00725.
BMC Cancer
- JIANG Z, Zhao F, Li B, He J, et al
Multidimensional comparative evaluation of first-line therapies for
extensive-stage small cell lung cancer: a systematic review and network
meta-analysis of clinical efficacy and safety profiles.
BMC Cancer. 2025;25:1292.
- LOBINGER D, Taylor N, Messner V, Seier S, et al
Circulating Hsp70: a tumor biomarker for lymph node metastases and early relapse
in thoracic cancer.
BMC Cancer. 2025;25:1297.
- LUAN X, Han X, Wang Z, Zhao L, et al
Heterogeneity of metastatic gastric cancer: solitary non-regional lymph node
metastasis and solitary lung metastasis showed better survival outcomes than
other metastatic patterns.
BMC Cancer. 2025;25:1287.
- LIN X, Liu S, Ding Y, Zhao J, et al
Contrasting tracheal, bronchus, and lung cancer burdens and care quality: a
comparative analysis of China and global trends.
BMC Cancer. 2025;25:1298.
- JAPUNTICH SJ, Sacasa NG, Cameron S, Balletto B, et al
Lung cancer screening experiences among patients with a smoking history and
primary care providers: a qualitative study.
BMC Cancer. 2025;25:1305.
Cancer
- STUDTS JL, Carter-Bawa L, Hamann HA, Smith RA, et al
The American Cancer Society National Lung Cancer Roundtable strategic plan:
Changing the lung cancer story: Addressing survivorship, stigma, and nihilism to
facilitate transformation.
Cancer. 2025;131:e35969.
- OLSON JMG, Knight JR, Copeland AM, Ohlander KA, et al
The American Cancer Society National Lung Cancer Roundtable strategic plan:
Addressing planning for lung cancer interventions at the state and local level
through the creation of the National Lung Cancer Roundtable Planning Tool.
Cancer. 2025;131:e35954.
Cancer Epidemiol Biomarkers Prev
- PESTARINO L, Fortner RT, Nost TH, Fotopoulos I, et al
Recommendations for validating omics prediction models: Insights from a lung
cancer RNA biomarker study.
Cancer Epidemiol Biomarkers Prev. 2025.
Chest
- MURGU S, Chen AC, Gilbert CR, Sterman DH, et al
A Prospective, Multicenter Evaluation of Safety and Diagnostic Outcomes With
Robotic-Assisted Bronchoscopy: Results of the Transbronchial Biopsy Assisted by
Robot Guidance in the Evaluation of Tumors of the Lung (TARGET) Trial.
Chest. 2025;168:539-555.
- YE Y, An P
Reassessing Communication Strategies in Lung Cancer Screening: Implications for
Patient-Centered Outcomes.
Chest. 2025;168:e55-e56.
Clin Cancer Res
- CIARDULLO C, Tobalina L, Carr TH, Szekeres P, et al
Early ctDNA dynamics inform first-line therapy in patients with extensive-stage
small cell lung cancer.
Clin Cancer Res. 2025 Aug 11. doi: 10.1158/1078-0432.CCR-25-2011.
Clin Lung Cancer
- TELLI TA, Tatli AM, Alan O, Keskin GY, et al
Real-World Outcomes in BRAF-Mutant Non-small Cell Lung Cancer: A Multicenter
Analysis From the Turkish Oncology Group.
Clin Lung Cancer. 2025 Jul 22:S1525-7304(25)00159.
Eur J Cancer
- YAMAGUCHI K, Takao S, Kanaji N, Hirakawa T, et al
The clinical potential of HMGB1 for the risk assessment of severe checkpoint
inhibitor pneumonitis: A prospective multicenter study (CS-Lung004).
Eur J Cancer. 2025;226:115606.
- ITALIANO A, Gautier O, Dupont J, Assi T, et al
The correlation of liquid biopsy genomic data to radiomics in colon, pancreatic,
lung and prostatic cancer patients.
Eur J Cancer. 2025;226:115609.
J Cancer Res Clin Oncol
- WU X, Fang K, Huang W, Chen G, et al
Combined small-cell lung cancer with adenocarcinoma: a rare case and literatures
review.
J Cancer Res Clin Oncol. 2025;151:230.
J Clin Oncol
- GONDI V, Pugh SL, Mehta MP, Wefel JS, et al
Hippocampal Avoidance During Prophylactic Cranial Irradiation for Patients With
Small Cell Lung Cancer: Randomized Phase II/III Trial NRG-CC003.
J Clin Oncol. 2025 Aug 11:JCO2500221. doi: 10.1200/JCO-25-00221.
- COOPER BT, Kondziolka D
Modern Targeted Radiation in Patients With Brain Metastases From Small Cell Lung
Cancer.
J Clin Oncol. 2025 Aug 12:JCO2501259. doi: 10.1200/JCO-25-01259.
JAMA Oncol
- ROLLE LD, Crane TE
Methodological Concerns With Lung Cancer Screening Estimates-Reply.
JAMA Oncol. 2025 Aug 14. doi: 10.1001/jamaoncol.2025.2581.
- BURUS T, McAfee CR, Hull PC
Methodological Concerns With Lung Cancer Screening Estimates.
JAMA Oncol. 2025 Aug 14. doi: 10.1001/jamaoncol.2025.2584.
Lancet
- SMIT EF, Dingemans AC
Adagrasib for KRAS(G12C) mutated advanced non-small-cell lung cancer.
Lancet. 2025;406:576-577.
- BARLESI F, Yao W, Duruisseaux M, Doucet L, et al
Adagrasib versus docetaxel in KRAS(G12C)-mutated non-small-cell lung cancer
(KRYSTAL-12): a randomised, open-label, phase 3 trial.
Lancet. 2025;406:615-626.
Lung Cancer
- CUMMINGS AL, Sussell J, Rosettie KL, Moustaid FE, et al
A treatment-impact model of alectinib for the prediction of recurrence and
associated costs in treating resectable ALK+ non-small cell lung cancer.
Lung Cancer. 2025;207:108701.
- YU Y, Pan Y, Zhou J, Mu S, et al
Dacomitinib in the treatment of EGFR-mutated non-small cell lung cancer with
brain metastases: an open-label, multicenter, phase II study.
Lung Cancer. 2025;207:108710.
- ALI AS, Irfan M
Second-hand smoke and survival in former smokers with lung cancer: time to act.
Lung Cancer. 2025 Aug 11:108713. doi: 10.1016/j.lungcan.2025.108713.
- CHATURVEDI A, Som A
Transcriptome analysis reveals crucial oncogenic and tumor suppressor miRNAs in
lung adenocarcinoma.
Lung Cancer. 2025;206:108540.
- HUBERT J, Moldovanu D, van den Bosch I, de Nijs K, et al
Impact of recruitment method on informed decision-making in lung cancer screening
in the 4-IN-THE-LUNG-RUN trial.
Lung Cancer. 2025;207:108686.
- LEE J, Kim M, Han HJ, Kim S, et al
Real-world survival outcomes of immune checkpoint inhibitor therapy after
standard treatment failure in EGFR-mutated NSCLC: A nationwide cohort study.
Lung Cancer. 2025;206:108682.
- PRONSATI N, Liu G, Bauer TM, Felip E, et al
Managing lorlatinib together: An overview and practical guide for patients by
ALK-positive NSCLC patients and medical experts.
Lung Cancer. 2025;206:108662.
- FUJINO K, Suda K, Yoshikawa M, Shien K, et al
Adjuvant therapy in pStage IA1-IIA lung adenocarcinoma (pN0): A multicenter study
focusing on EGFR mutations and recurrence patterns (CReGYT-01 EGFR study).
Lung Cancer. 2025;206:108672.
- LU F, Lv C, Yang X, Zhuo M, et al
Icotinib plus chemotherapy as neoadjuvant treatment for resectable stage II-IIIB
EGFR-mutant lung adenocarcinoma: a phase II study (NEOIPOWER).
Lung Cancer. 2025;206:108676.
- NIEDERMAIER B, Rolf E, Allgauer M, Klotz LV, et al
Prognostic impact of lepidic growth in intermediate and high-grade lung
adenocarcinoma.
Lung Cancer. 2025;206:108674.
- LYNCH GA, Symonds J, Morley A, Azubuike-Dyer E, et al
Serum mesothelin as a response biomarker in pleural mesothelioma.
Lung Cancer. 2025;206:108670.
- PANDEY A, Gomez E, Soto A, Jr MA, et al
A novel murine carcinogen-induced model recapitulates the progression and
heterogeneity of human lung adenocarcinoma.
Lung Cancer. 2025;206:108581.
- DUMANE V, Runnels J, Flores R, Wolf A, et al
Long term side effects after volumetric modulated arc therapy to the pleura in
patients with malignant pleural mesothelioma.
Lung Cancer. 2025;206:108639.
- GAGNE A, Alessi JVM, Ricciuti B, Lamberti G, et al
Acquired SMARCA4 alterations: An uncommon contributor to cancer progression in
lung adenocarcinomas.
Lung Cancer. 2025;206:108644.
- MEDUSA PM, Carro N, Morgillo F, Guida GD, et al
Predictive role of functional respiratory tests in LUng toxicity in stage III
NSCLC treated with chemo-, raDIO- and immuno-therapy: PRELUDIO TRIAL.
Lung Cancer. 2025;206:108617.
- ZOLOV S, Chuikov S, Katkam SK, Chockley PJ, et al
Cell adhesion molecule-1 is a promising target for chimeric antigen receptors in
lung adenocarcinoma.
Lung Cancer. 2025;206:108643.
- LANGER S, Medenwald D, Vordermark D, Schuette W, et al
Therapeutic modalities for superior sulcus tumor (Pancoast) tumor - A systematic
review.
Lung Cancer. 2025;206:108640.
Nat Genet
- KLOTZER KA, Abedini A, Li S, Balzer MS, et al
Analysis of individual patient pathway coordination in a cross-species
single-cell kidney atlas.
Nat Genet. 2025;57:1922-1934.
Oncogene
- LIU L, Chen S, Lei Y, Lin Z, et al
REPS2 attenuates cancer stemness through inhibiting Wnt signaling by autophagy
mediated degradation of beta-catenin.
Oncogene. 2025;44:2942-2955.
Oncol Rep
- LEI Y, Guo W, Chen B, Chen L, et al
[Retracted] Tumor?released lncRNA H19 promotes gefitinib resistance via packaging
into exosomes in non?small cell lung cancer.
Oncol Rep. 2025;54:140.
PLoS One
- ABDOLLAHI A, Favata M, Weber M, Roman V, et al
The FGFR inhibitor pemigatinib overcomes cancer drug resistance to KRAS G12C
inhibitors in mesenchymal lung cancer.
PLoS One. 2025;20:e0327588.
Free Medical Abstracts
Privacy Policy
Sponsors
Share
© Amedeo 1997-2016